

Journal of Visualized Experiments

Isolation of mouse myoblasts for differentiation and imaging of mature myofibers --Manuscript Draft--

Manuscript Number:	JoVE55141R1
Full Title:	Isolation of mouse myoblasts for differentiation and imaging of mature myofibers
Article Type:	Invited Methods Article - JoVE Produced Video
Keywords:	muscle, myofiber, differentiation, in vitro, microscopy, development
Manuscript Classifications:	1.11.620.249: Muscle Fibers, Skeletal; 1.11.620.249.850: Myofibrils; 1.11.620.249.850.700: Sarcomeres; 1.11.635.500: Myoblasts, Skeletal; 1.2.633.567: Muscle, Skeletal; 12.1.224.308.410: Imaging, Three-Dimensional; 12.1.240.960.399: Time-Lapse Imaging; 5.5.240.249: Cell Culture Techniques; 7.11.427.590.560.590: Muscle Development; 8.1.158.273.190: Cell Biology
Corresponding Author:	Mafalda Ramos Pimentel Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa Lisboa, PORTUGAL
Corresponding Author Secondary Information:	
Corresponding Author E-Mail:	mrpimentel@medicina.ulisboa.pt
Corresponding Author's Institution:	Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa
Corresponding Author's Secondary Institution:	
First Author:	Mafalda Ramos Pimentel
First Author Secondary Information:	
Other Authors:	Sestina Falcone Edgar Rodrigues Gomes
Order of Authors Secondary Information:	
Abstract:	<p>Skeletal muscle is composed of myofibers, the biggest cells in the mammalian body and one of the few syncytia. How the complex and evolutionary conserved structures that compose it are assembled remains under investigation. Their size and physiological features often constrain manipulation and imaging applications. The culture of immortalized cell lines is widely used but it can only replicate the early steps of differentiation.</p> <p>Here we describe a protocol that enables easy genetic manipulation of myofibers originated from primary mouse myoblasts. After one week of differentiation the myofibers display contractility, aligned sarcomeres and triads as well as peripheral nuclei. The entire differentiation process can be followed by live imaging or immunofluorescence.</p> <p>This system combines advantages of the existing ex vivo and in vitro protocols. The possibility of easy and efficient transfection as well as the ease of access to all differentiation stages broadens the potential applications. Myofibers can subsequently be used to address not only relevant developmental and cell biology questions, as well as to reproduce muscle disease phenotypes for clinical applications.</p>
Author Comments:	Although the invitation for submission was sent to the first author, Edgar Gomes is the corresponding author as specified in the manuscript. In the submission website the corresponding author could not be modified.
Additional Information:	
Question	Response
If this article needs to be "in-press" by a	

<p>certain date to satisfy grant requirements, please indicate the date below and explain in your cover letter.</p>	
---	--

Dr. Nandita SINGH
Senior Science Editor
JoVE

Lisbon, June 16th 2016


Dear Dr. Singh,

Please find enclosed our article entitled “**Isolation of mouse myoblasts for differentiation and imaging of mature myofibers**” for consideration for publication in JoVE.

Our laboratory is interested in studying mechanisms of myofiber differentiation and how myofiber physiology is altered in different pathological conditions. We recently developed a system to differentiate myofiber in vitro and use it to study the molecular mechanisms that are altered during centronuclear myopathies and myotonic dystrophies (Falcone et al. EMBO Molecular Medicine, 2014). Therefore we believe that our report will be of interest to the broad scientific community of JoVE readers interested in studying mechanism of skeletal muscle differentiation and muscle disorders.

We thank you for your consideration.

Yours truly,



Edgar Gomes, Ph.D.

Phone: +351 217999515
edgargomes@medicina.ulisboa.pt

TITLE:

Isolation of mouse myoblasts for differentiation and imaging of mature myofibers

AUTHORS:

Pimentel, Mafalda R
Molecular Medicine Institute, Faculty of Medicine
University of Lisbon
Lisboa, Portugal
mrpimentel@medicina.ulisboa.pt

Falcone, Sestina
Myology Research Center
UM76-INSERM U974-CNRS FRE 361 Sorbonne University
UPMC University of Paris 6
Paris, France
sestinaf@gmail.com

Gomes, Edgar R
Instituto de Medicina Molecular, Molecular Medicine Institute
Faculdade de Medicina, Universidade de Lisboa Faculty of Medicine
University of Lisbon
Lisboa, Portugal
and
Myology Research Center
UM76-INSERM U974-CNRS FRE 361 Sorbonne University
UPMC University of Paris 6
Paris, France
edgargomes@medicina.ulisboa.pt

CORRESPONDING AUTHOR:

Gomes, Edgar R
edgargomes@medicina.ulisboa.pt

KEYWORDS:

muscle, myofiber, differentiation, *in vitro*, microscopy, development

SHORT ABSTRACT:

Muscle cells are among the most complex eukaryotic cells. We present a protocol for the *in vitro* differentiation of highly mature myofibers that allows for genetic manipulation and clear imaging during all developmental stages.

LONG ABSTRACT:

Skeletal muscle is composed of myofibers, the biggest cells in the mammalian body and one of the few syncytia. How the complex and evolutionarily-conserved structures that compose it are

assembled remains under investigation. Their size and physiological features often constrain manipulation and imaging applications. The culture of immortalized cell lines is widely used, but it can only replicate the early steps of differentiation.

Here, we describe a protocol that enables easy genetic manipulation of myofibers originating from primary mouse myoblasts. After one week of differentiation, the myofibers display contractility, aligned sarcomeres and triads, as well as peripheral nuclei. The entire differentiation process can be followed by live imaging or immunofluorescence. This system combines the advantages of the existing *ex vivo* and *in vitro* protocols. The possibility of easy and efficient transfection as well as the ease of access to all differentiation stages broadens the potential applications. Myofibers can subsequently be used not only to address relevant developmental and cell biology questions, but also to reproduce muscle disease phenotypes for clinical applications.

INTRODUCTION:

Skeletal muscle composes up to 40% of the human body weight¹. Muscle-associated disorders represent an immense health and economic burden². How this highly complex and organized tissue is formed, maintained, and regenerated constitutes an extensive and well-established research field. Depending on the specific scientific interest, the most suited approach can range from simple myotube cultures to complex *in vivo* models³⁻⁶.

The goal of this protocol is to provide an *in vitro* system that allows for the monitoring of myogenesis through live imaging and immunofluorescence. Compared to traditional approaches, this system offers a very complete and dynamic insight into the mouse myogenic process. Cells can be followed from the myoblast stage to the mature, multinucleated myofiber displaying transversal triads and peripheral nuclei⁷. This maturation level can be achieved using regular cell culture equipment, without the need for complex stimulatory or mechanical apparatuses. Although some successful *in vitro* systems have been reported^{8,9}, to our knowledge, this is the only protocol generating mature mouse myofibers with T-tubules transversally paired with sarcoplasmic reticulum (SR). Thus, this *in vitro* system can be used to study the molecular mechanisms of triad formation, which are still poorly understood¹⁰.

A further advantage of using this system is the availability of validated mouse-targeted resources, such as antibodies, drugs, and RNAi tools. The relatively simple protocol does not require laborious steps, highly-skilled manipulation, or expensive and dedicated equipment. Matured myofibers start appearing after 5 days of culture differentiation⁷, displaying contractility coupled with calcium sparks (unpublished data). In one week, the different developmental stages of one of the most complex cells in the mammalian body can be studied in combination with a variety of *in vitro* assays.

PROTOCOL:

Note: One mouse yields sufficient myoblasts for approximately two 35-mm dishes or two live-imaging dishes, so plan matings, dissection, and coating (step 2.6) accordingly. Since myoblasts

are isolated through sequential centrifugations and pre-plating, the protocol should be done in batches of 5 to 10 animals.

All procedures involving animal subjects were approved by the Animal Ethics Committee of Molecular Medicine Institute.

1. Dissection of neonatal mice hind limb muscles

1.1) Prepare all solutions in advance (Materials Table) and sterilize by filtration (0.22 μ m filter). Make sure all media are at 37 °C before addition to the cells, except the formulations containing basement membrane matrix (*e.g.*, Matrigel).

1.2) Sterilize the dissection material (one each of: curved scissors, straight scissors, regular forceps, and fine-tip forceps) and the work bench by wiping them with 70% ethanol.

1.3) Prepare a 100-mm petri dish with 5 mL of Dulbecco's Phosphate Buffered Saline (DPBS) for muscle collection and keep it on ice until the mincing step.

1.4) Decapitate P6-P8 mice with straight scissors and sterilize the skin with 70% ethanol.

1.5) Make an incision in the back skin and pull it gently towards the hind limbs until it is removed, completely exposing the hind-limb musculature.

1.6) Use the forceps to remove fat tissue without damaging the muscles.

1.7) To remove the tibialis anterior, extensor digitorum longus, and gastrocnemius, keep the limb stretched and bend the paw to expose the heel tendons. Use the curved scissors to separate muscle from bone, starting from the tendons, by gently sliding and cutting upwards. Excise the muscles and place them in iced DPBS.

1.8) Isolate the quadriceps by pinching the muscle with fine-tip forceps and cutting around it without damaging the femur or the knee joint.

1.9) After dissecting all animals, proceed to a sterile laminar flow cell culture hood, where all the following steps should be performed.

2. Myoblast isolation

2.1) Remove the excess of DPBS. Mince the tissue with sterilized curved scissors in order to obtain a uniform mass.

2.2) Collect the minced tissue in a 50-mL conical centrifuge tube using 5 mL of digestion mix and incubate it with agitation at 37 °C for 90 min.

2.3) Stop the digestion by adding 6 mL of dissection medium and centrifuge the suspension for 5 min at 75 x g to pellet the remaining tissue.

2.4) Carefully collect the supernatant and centrifuge it at 350 x g for 5 min; resuspend it in 5 mL of dissection medium.

2.5) Filter the cell suspension through a 40 µm cell strainer. Add 25 mL of dissection medium and pre-plate it in a 150-mm dish for 4 h in a cell culture incubator (37 °C and 5% CO₂) to allow for fibroblast adhesion.

2.6) While pre-plating, coat dishes with 500 µL of basement membrane matrix diluted 1:100 in cold IMDM for 1 h at room temperature (RT). Wash once with DPBS and plate the cells immediately (step 2.8) or leave with growth medium until plating.

2.7) After pre-plating, collect the supernatant and centrifuge it at 350 x g for 10 min.

2.8) Resuspend it in growth medium and count the cells on a hemocytometer. Adjust the volume so that between 150,000 and 250,000 cells are plated per basement membrane matrix-coated dish. Keep the cells in a cell culture incubator.

3. Myofiber differentiation

Note: After 3 days, the cells should start to fuse and form myotubes at around 70% confluency (Figure 1B).

3.1) At this point, transfect the cells, if desired, with a siRNA or DNA of interest. If the cells are not to be transfected, change directly to differentiation medium and skip to step 3.4.

3.2) Transfect with transfection reagents following the manufacturer's instructions. Incubate the cells for 5 h with siRNA-lipid complexes (20 nM + 1 µL of reagent) or DNA-lipid complexes (1 µg + 1 µL of reagent). Optimize the siRNA and DNA concentrations if necessary.

3.3) Wash them once with differentiation medium and then switch to new differentiation medium.

3.4) The following day, dilute the basement membrane matrix 1:2 in ice-cold differentiation medium. Remove the existing medium and add 200 µL of ice-cold matrix to each dish.

3.5) Incubate for 30 min in a cell culture incubator.

3.6) Supplement the differentiation medium with agrin (100 ng/mL) and carefully add 2 mL to the cells.

3.7) Carefully change half of the medium every 2 days, always supplementing with agrin to a final concentration of 100 ng/µL.

3.8) Monitor cell differentiation and viability. Depending on a variety of factors (such as fetal bovine serum and chicken embryo extract origins), the cells might take between 5 to 10 differentiation days to reach full maturation (Figure 2).

4. Immunostaining in glass-bottom dishes

4.1) For immunostaining, at any time-point of interest, wash the cells once with DPBS and fix them with 4% PFA at RT for 10 min.

4.2) Wash them 2 times with DPBS. At this point, the cells can be stored at 4 °C.

4.3) Permeabilize them with 0.5% Triton X-100 for 5 min at RT.

4.4) Wash them twice with PBS and block with blocking solution for 30 min at RT.

4.5) Incubate them with primary antibody diluted in blocking solution overnight at 4 °C.

4.6) Wash them 3 times with DPBS for 5 min at RT.

4.7) Incubate them with the secondary antibody and 0.2 µg/mL of DAPI for 1 h at RT.

4.8) Wash them 3 times with DPBS for 5 min at RT.

4.9) Add 200 µL of mounting medium and proceed to imaging.

REPRESENTATIVE RESULTS:

The extent of myofiber development is mostly determined by the purity and viability of the isolated myoblasts. The adhesion, proliferation, and fusion capacity can be used to empirically access those parameters (Figure 1 A-B). At proliferation day 2, myoblasts should have adhered and should display the typical fusiform shape. Proliferation is expected to happen extensively at this stage, leading to spontaneous myotube formation the following day (Figure 1B).

Cell confluency might need slight adjustments. It should be increased if myoblasts take more than 3 days to proliferate and fuse. It should be decreased if myofibers are not allowed to grow and elongate relatively straight due to their density. Confluency typically decreases from the center to the periphery of the dish, so the best myofibers should be found towards the outer regions.

Myotubes will quickly elongate and display multiple centrally-aligned nuclei (Figure 1C). By day 5, some cells start acquiring striations and moving their nuclei to the periphery. The number of myofibers with mature characteristics will increase with time as well as with cell thickness (Figure 1D).

The degree of differentiation can be further observed by immunofluorescence. Myofibers fixed at differentiation day 8 present transversal triads. This can be confirmed by imaging

components of the T-tubules (DHP) and the SR (triadin), which are expected to co-localize at the triads (Figure 2).

The functionality of myofibers can be addressed by live imaging. From differentiation day 3 onwards, the cells display spontaneous twitching. By transfecting a calcium sensor (*e.g.*, GCaMP6f¹¹), it is possible to observe that the contractions are coupled with calcium peaks (Figure 3).

Using this system, we were able to identify a novel molecular pathway that is disrupted in centronuclear myopathies and myotonic dystrophies, which can therefore be a novel target for innovative molecular therapies⁷. We have also adapted this method to study the development of the neuromuscular junction (NMJ)¹². Through the co-culture with rat spinal cord explants, we have described a role for dynein in NMJ formation¹³.

Figure 1: Developmental stages of the myoblast culture.

A) At proliferation day 2, myoblasts have adhered and started proliferating. B) At proliferation day 3, a confluency of 60-80% is reached, and myoblasts start fusing spontaneously. C) At differentiation day 3, myotubes containing centrally-located nuclei are predominant. D) From differentiation day 5 onwards (*e.g.*, day 8), myofibers start exhibiting striations and peripheral nuclei and begin to thicken. Scale bar: 50 μm .

Figure 2: Representative confocal image of a day-8 myofiber immunostain.

A) Immunostaining for dihydropyridine receptor (DHPR, top panel) and triadin (TRDN, middle panel). An overlay of the DHPR, TRDN, and DAPI channels shows co-localization of the triad components. B) An intensity profile of the yellow line drawn in A. C) A 3D image of volume rendering of myofibers stained for α -actinin (green) and DAPI (blue). Scale bar and grid width: 5 μm .

Figure 3: Live imaging of calcium levels in myofibers with spontaneous twitching.

A) High-speed time-lapse (20 ms frames) microscopy of a calcium spark in a twitching myofiber. Calcium was detected through the expression of GCaMP6f (Addgene plasmid #40755). B) Quantification of the fluorescence intensity over time for the calcium sensor in panel A.

DISCUSSION:

The use of this protocol for the cultivation of primary myoblasts gives rise to a special niche that greatly nurtures the development of myofibers. This is partially due to other cell types that are also present in very small numbers. A balance between myoblast concentration and culture purity must be achieved. A good cell culture also depends on the quality of the products used for the medium formulation. All products derived from animal sources should be thoroughly tested. In our experience, the digestion conditions should also be monitored.

As usual for primary cultures, experimental variability can be higher than in studies with isolated fibers or immortalized myoblasts. This variability can be diminished by the standardization of medium and digestion components, mice age and size, and the time points

for culture manipulation and results collection. Nevertheless, the advantage of scrutinizing in real time the intricate mechanisms necessary for myofiber development greatly surpasses the variability drawback.

This protocol confers the advantages of *in vitro* approaches without compromising cell differentiation. Myofibers mature until triads are formed and contractions are coupled to calcium sparks. These functional outputs can be accessed in different experimental conditions. Furthermore, there can be many technical variations made to the protocol. Myoblasts can be harvested from neonatal mice with mutations of interest relating to muscle development. Cells can be lysed for biochemical analysis at different differentiation time points. Calcium indicators can be added to the culture to follow its dynamics. Optogenetic constructs can be used to enforce certain signaling pathways or to induce specific local responses. Finally, the myofibers can be co-cultured with other cells types to study their interactions.

ACKNOWLEDGMENTS:

This work was supported by the European Research Council (ERG) and EMBO installation (ERG) and by a PhD fellowship from the Fundação para a Ciência e Tecnologia (MP).





DISCLOSURES:

The authors have nothing to disclose.

REFERENCES:

1. Janssen, I., Heymsfield, S. B., Wang, Z. & Ross, R. Skeletal muscle mass and distribution in 468 men and women aged 18–88 yr. *J Appl Physiol* **89** (1), 81–88 (2000).
2. Manring, H., Abreu, E., Brotto, L., Weisleder, N. & Brotto, M. Novel excitation-contraction coupling related genes reveal aspects of muscle weakness beyond atrophy—new hopes for treatment of musculoskeletal diseases. *Front Physiol* **5**, 37, doi:10.3389/fphys.2014.00037 (2014).
3. Yaffe, D. & Saxel, O. Serial passaging and differentiation of myogenic cells isolated from dystrophic mouse muscle. *Nature* **270** (5639), 725–727 (1977).
4. Pasut, A., Jones, A. E. & Rudnicki, M. A. Isolation and Culture of Individual Myofibers and their Satellite Cells from Adult Skeletal Muscle. *J Vis Exp* (73), doi:10.3791/50074 (2013).
5. Meng, H., Janssen, P. M. L., *et al.* Tissue Triage and Freezing for Models of Skeletal Muscle Disease. *J Vis Exp* (89), doi:10.3791/51586 (2014).
6. Demonbreun, A. R. & McNally, E. M. DNA Electroporation, Isolation and Imaging of Myofibers. *J Vis Exp* (106), doi:10.3791/53551 (2015).
7. Falcone, S., Roman, W., *et al.* N-WASP is required for Amphiphysin-2/BIN1-dependent nuclear positioning and triad organization in skeletal muscle and is involved in the pathophysiology of centronuclear myopathy. *EMBO Mol Med* **6** (11), 1455–1475, doi:10.15252/emmm.201404436 (2014).
8. Flucher, B. E., Phillips, J. L. & Powell, J. A. Dihydropyridine receptor alpha subunits in normal and dysgenic muscle in vitro: expression of alpha 1 is required for proper targeting and distribution of alpha 2. *J Cell Biol* **115** (5), 1345–1356, doi:10.1083/jcb.115.5.1345 (1991).

9. Cooper, S. T., Maxwell, A. L., *et al.* C2C12 co-culture on a fibroblast substratum enables sustained survival of contractile, highly differentiated myotubes with peripheral nuclei and adult fast myosin expression. *Cell Motil Cytoskeleton* **58** (3), 200–211, doi:10.1002/cm.20010 (2004).
10. Al-Qusairi, L. & Laporte, J. T-tubule biogenesis and triad formation in skeletal muscle and implication in human diseases. *Skelet Muscle* **1**, 26, doi:10.1186/2044-5040-1-26 (2011).
11. Vilmont, V., Cadot, B., Ouanounou, G. & Gomes, E. R. A system to study mechanisms of neuromuscular junction development and maintenance. *Development*, dev.130278, doi:10.1242/dev.130278 (2016).
12. Vilmont, V., Cadot, B., Vezin, E., Le Grand, F. & Gomes, E. R. Dynein disruption perturbs post-synaptic components and contributes to impaired MuSK clustering at the NMJ: implication in ALS. *Sci Rep* **6**, 27804, doi:10.1038/srep27804 (2016).








Figure 3

A



B



Name of Reagent/ Equipment	Company	Catalog Number
Dispase II	Gibco	17105041
Collagenase type V	Sigma-Aldrich-Aldrich	C9263
IMDM, Glutamax supplemented	Gibco	31980022
Matrigel Growth reduced factor	Corning	354230
Chicken Embryo Extract	MP biomedical	2850145
Recombinant rat agrin	R&D systems	550-AG-100
Penicillin-Streptomycin	Thermo Fisher Scientific	15140122
Horse Serum	GE Healthcare	11581831
Lipofectamine RNAiMAX	Invitrogen	13778-150
Lipofectamine LTX	Invitrogen	15338-100
Lipofectamine 2000	Invitrogen	11668030
DPBS	Gibco	14190094
Fetal Bovine Serum	Eurobio	CVFSVF0001
Cell strainer	Corning	21008-949
Fluorodishes	World precision instruments	FD35-100
Triton X-100	Sigma-Aldrich	T9284
16% PFA (Paraformaldehyde)	Science Services GmbH	E15710
Goat Serum	Sigma-Aldrich	G9023
BSA (Bovine Serum Albumine)	Sigma-Aldrich	A7906
Saponine	Sigma-Aldrich	47036
DAPI	Sigma-Aldrich	D9542
Fluoromount-G	SouthernBiotech	0100-01

Solutions and Media

Digestion Mix	in DPBS 5 mg/ml collagenase 3.5 mg/ml dispase sterile filtered, can be stored in working aliquotes for 2 weeks at
Dissection Medium	in IMDM Glutamax supplemented 10% FBS

1% Penicillin-Streptomycin
sterile filtered

Growth Medium

in IMDM Glutamax supplemented
20% FBS
1% Chicken Embryo Extract
1% Penicillin-Streptomycin
sterile filtered

Differentiation Medium

in IMDM Glutamax supplemented
2% Horse Serum
1% Penicillin-Streptomycin
sterile filtered

Blocking Solution

in DPBS
10% Goat Serum
5% BSA

add 0.1% saponine when incubating
with primary and secondary antibodies

Comments/Description

protein concentration of the lot should be around 10mg/ml and endotoxin result should be <1.5
it is also possible to prepare in the lab (Danoviz ME, Yablonka-Reuveni Z. Methods Mol Biol (2012))

used to transfect siRNA
used to transfect DNA
used to transfect siRNA plus DNA

dishes used to cultivate cells for live imaging

use at 200ng/ul

-20 °C



1 Alewife Center #200
Cambridge, MA 02140
tel. 617.945.9051
www.jove.com

ARTICLE AND VIDEO LICENSE AGREEMENT

Title of Article:

Isolation of mouse myoblasts for differentiation and imaging of mature myofibers

Author(s):

Mafalda Ramos Pimentel, Sestina Falcone, Edgar R. Gomes

Item 1 (check one box): The Author elects to have the Materials be made available (as described at <http://www.jove.com/publish>) via: ☐ Standard Access ☒ Open Access

Item 2 (check one box):

- ☒ The Author is NOT a United States government employee.
- ☐ The Author is a United States government employee and the Materials were prepared in the course of his or her duties as a United States government employee.
- ☐ The Author is a United States government employee but the Materials were NOT prepared in the course of his or her duties as a United States government employee.

ARTICLE AND VIDEO LICENSE AGREEMENT

1. **Defined Terms.** As used in this Article and Video License Agreement, the following terms shall have the following meanings: “**Agreement**” means this Article and Video License Agreement; “**Article**” means the article specified on the last page of this Agreement, including any associated materials such as texts, figures, tables, artwork, abstracts, or summaries contained therein; “**Author**” means the author who is a signatory to this Agreement; “**Collective Work**” means a work, such as a periodical issue, anthology or encyclopedia, in which the Materials in their entirety in unmodified form, along with a number of other contributions, constituting separate and independent works in themselves, are assembled into a collective whole; “**CRC License**” means the Creative Commons Attribution-Non Commercial-No Derivs 3.0 Unported Agreement, the terms and conditions of which can be found at: <http://creativecommons.org/licenses/by-nc-nd/3.0/legalcode>; “**Derivative Work**” means a work based upon the Materials or upon the Materials and other pre-existing works, such as a translation, musical arrangement, dramatization, fictionalization, motion picture version, sound recording, art reproduction, abridgment, condensation, or any other form in which the Materials may be recast, transformed, or adapted; “**Institution**” means the institution, listed on the last page of this Agreement, by which the Author was employed at the time of the creation of the Materials; “**JoVE**” means MyJoVE Corporation, a Massachusetts corporation and the publisher of *The Journal of Visualized Experiments*; “**Materials**” means the Article and / or the Video; “**Parties**” means the Author and JoVE; “**Video**” means any video(s) made by the Author, alone or in conjunction with any other parties, or by JoVE or its affiliates or agents, individually or in collaboration with the Author or any other parties, incorporating all or any portion of the Article, and in which the Author may or may not appear.

2. **Background.** The Author, who is the author of the Article, in order to ensure the dissemination and protection of the Article, desires to have the JoVE publish the Article and create and transmit videos based on the Article. In furtherance of such goals, the Parties desire to memorialize in this Agreement the respective rights of each Party in and to the Article and the Video.

3. **Grant of Rights in Article.** In consideration of JoVE agreeing to publish the Article, the Author hereby grants to JoVE, subject to **Sections 4** and **7** below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Article in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Article into other languages, create adaptations, summaries or extracts of the Article or other Derivative Works (including, without limitation, the Video) or Collective Works based on all or any portion of the Article and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. If the “Open Access” box has been checked in **Item 1** above, JoVE and the Author hereby grant to the public all such rights in the Article as provided in, but subject to all limitations and requirements set forth in, the CRC License.

ARTICLE AND VIDEO LICENSE AGREEMENT

4. Retention of Rights in Article. Notwithstanding the exclusive license granted to JoVE in **Section 3** above, the Author shall, with respect to the Article, retain the non-exclusive right to use all or part of the Article for the non-commercial purpose of giving lectures, presentations or teaching classes, and to post a copy of the Article on the Institution's website or the Author's personal website, in each case provided that a link to the Article on the JoVE website is provided and notice of JoVE's copyright in the Article is included. All non-copyright intellectual property rights in and to the Article, such as patent rights, shall remain with the Author.

5. Grant of Rights in Video – Standard Access. This **Section 5** applies if the "Standard Access" box has been checked in **Item 1** above or if no box has been checked in **Item 1** above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby acknowledges and agrees that, Subject to **Section 7** below, JoVE is and shall be the sole and exclusive owner of all rights of any nature, including, without limitation, all copyrights, in and to the Video. To the extent that, by law, the Author is deemed, now or at any time in the future, to have any rights of any nature in or to the Video, the Author hereby disclaims all such rights and transfers all such rights to JoVE.

6. Grant of Rights in Video – Open Access. This **Section 6** applies only if the "Open Access" box has been checked in **Item 1** above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby grants to JoVE, subject to **Section 7** below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Video in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Video into other languages, create adaptations, summaries or extracts of the Video or other Derivative Works or Collective Works based on all or any portion of the Video and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. For any Video to which this Section 6 is applicable, JoVE and the Author hereby grant to the public all such rights in the Video as provided in, but subject to all limitations and requirements set forth in, the CRC License.

7. Government Employees. If the Author is a United States government employee and the Article was prepared in the course of his or her duties as a United States government employee, as indicated in **Item 2** above, and any of the licenses or grants granted by the Author hereunder exceed the scope of the 17 U.S.C. 403, then the rights granted hereunder shall be limited to the maximum rights permitted under such

statute. In such case, all provisions contained herein that are not in conflict with such statute shall remain in full force and effect, and all provisions contained herein that do so conflict shall be deemed to be amended so as to provide to JoVE the maximum rights permissible within such statute.

8. Likeness, Privacy, Personality. The Author hereby grants JoVE the right to use the Author's name, voice, likeness, picture, photograph, image, biography and performance in any way, commercial or otherwise, in connection with the Materials and the sale, promotion and distribution thereof. The Author hereby waives any and all rights he or she may have, relating to his or her appearance in the Video or otherwise relating to the Materials, under all applicable privacy, likeness, personality or similar laws.

9. Author Warranties. The Author represents and warrants that the Article is original, that it has not been published, that the copyright interest is owned by the Author (or, if more than one author is listed at the beginning of this Agreement, by such authors collectively) and has not been assigned, licensed, or otherwise transferred to any other party. The Author represents and warrants that the author(s) listed at the top of this Agreement are the only authors of the Materials. If more than one author is listed at the top of this Agreement and if any such author has not entered into a separate Article and Video License Agreement with JoVE relating to the Materials, the Author represents and warrants that the Author has been authorized by each of the other such authors to execute this Agreement on his or her behalf and to bind him or her with respect to the terms of this Agreement as if each of them had been a party hereto as an Author. The Author warrants that the use, reproduction, distribution, public or private performance or display, and/or modification of all or any portion of the Materials does not and will not violate, infringe and/or misappropriate the patent, trademark, intellectual property or other rights of any third party. The Author represents and warrants that it has and will continue to comply with all government, institutional and other regulations, including, without limitation all institutional, laboratory, hospital, ethical, human and animal treatment, privacy, and all other rules, regulations, laws, procedures or guidelines, applicable to the Materials, and that all research involving human and animal subjects has been approved by the Author's relevant institutional review board.

10. JoVE Discretion. If the Author requests the assistance of JoVE in producing the Video in the Author's facility, the Author shall ensure that the presence of JoVE employees, agents or independent contractors is in accordance with the relevant regulations of the Author's institution. If more than one author is listed at the beginning of this Agreement, JoVE may, in its sole discretion, elect not take any action with respect to the Article until such time as it has received complete, executed Article and Video License Agreements from each such author. JoVE reserves the right, in its absolute and sole discretion and without giving any reason therefore, to accept or decline any work submitted to JoVE. JoVE and its employees, agents and independent contractors shall have

ARTICLE AND VIDEO LICENSE AGREEMENT

full, unfettered access to the facilities of the Author or of the Author's institution as necessary to make the Video, whether actually published or not. JoVE has sole discretion as to the method of making and publishing the Materials, including, without limitation, to all decisions regarding editing, lighting, filming, timing of publication, if any, length, quality, content and the like.

11. **Indemnification.** The Author agrees to indemnify JoVE and/or its successors and assigns from and against any and all claims, costs, and expenses, including attorney's fees, arising out of any breach of any warranty or other representations contained herein. The Author further agrees to indemnify and hold harmless JoVE from and against any and all claims, costs, and expenses, including attorney's fees, resulting from the breach by the Author of any representation or warranty contained herein or from allegations or instances of violation of intellectual property rights, damage to the Author's or the Author's institution's facilities, fraud, libel, defamation, research, equipment, experiments, property damage, personal injury, violations of institutional, laboratory, hospital, ethical, human and animal treatment, privacy or other rules, regulations, laws, procedures or guidelines, liabilities and other losses or damages related in any way to the submission of work to JoVE, making of videos by JoVE, or publication in JoVE or elsewhere by JoVE. The Author shall be responsible for, and shall hold JoVE harmless from, damages caused by lack of sterilization, lack of cleanliness or by contamination due to the making of a video by JoVE its employees, agents or independent contractors. All sterilization, cleanliness or decontamination procedures shall be solely the responsibility of the Author and shall be undertaken at the Author's


expense. All indemnifications provided herein shall include JoVE's attorney's fees and costs related to said losses or damages. Such indemnification and holding harmless shall include such losses or damages incurred by, or in connection with, acts or omissions of JoVE, its employees, agents or independent contractors.

12. **Fees.** To cover the cost incurred for publication, JoVE must receive payment before production and publication the Materials. Payment is due in 21 days of invoice. Should the Materials not be published due to an editorial or production decision, these funds will be returned to the Author. Withdrawal by the Author of any submitted Materials after final peer review approval will result in a US\$1,200 fee to cover pre-production expenses incurred by JoVE. If payment is not received by the completion of filming, production and publication of the Materials will be suspended until payment is received.

13. **Transfer, Governing Law.** This Agreement may be assigned by JoVE and shall inure to the benefits of any of JoVE's successors and assignees. This Agreement shall be governed and construed by the internal laws of the Commonwealth of Massachusetts without giving effect to any conflict of law provision thereunder. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed to be one and the same agreement. A signed copy of this Agreement delivered by facsimile, e-mail or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Agreement.

A signed copy of this document must be sent with all new submissions. Only one Agreement required per submission.

CORRESPONDING AUTHOR:

Name:	Edgar R. Gomes	
Department:		
Institution:	Instituto de Medicina Molecular	
Article Title:	A system to study the formation of functional neuromuscular junctions between highly differentiated mouse myofibers and rat motor neurons	
Signature:		Date: 15 June 2016

Please submit a signed and dated copy of this license by one of the following three methods:

- 1) Upload a scanned copy of the document as a pdf on the JoVE submission site;
- 2) Fax the document to +1.866.381.2236;
- 3) Mail the document to JoVE / Attn: JoVE Editorial / 1 Alewife Center #200 / Cambridge, MA 02139

For questions, please email submissions@jove.com or call +1.617.945.9051

Editorial comments:

The manuscript has been modified by the Science Editor to comply with the JoVE formatting standard. Please maintain the current formatting throughout the manuscript. The updated manuscript (55141_R0_062316.docx) is located in your Editorial Manager account. In the revised PDF submission, there is a hyperlink for downloading the .docx file. Please download the .docx file and use this updated version for any future revisions.

Changes to be made by the Author(s):

1. Please take this opportunity to thoroughly proofread the manuscript to ensure that there are no spelling or grammar issues. The JoVE editor will not copy-edit your manuscript and any errors in the submitted revision may be present in the published version.

2. Please abbreviate all journal titles.[done](#)

3. Please include an ethics statement before your numbered protocol steps, indicating that the protocol follows the animal care guidelines of your institution.[done](#)

4. 1.1: Sterile filter how? .22 um filter?[done](#)

5. Animal care note – Decapitation without prior anesthesia might present a problem for vet review [The protocols described here were previously accepted by ethics committees in France and Portugal. The decapitation is done in newborns \(P6-p8\) as stated in the protocol](#)

6. Formatting

-In the Author Affiliations, please use English translations for university/department names.[done](#)

-The sentence "Using this system we were able to identify a novel molecular pathway that is disrupted in centronuclear myopathies and myotonic dystrophies, and therefore can be a novel target for innovative molecular therapies7." in the Introduction is better-suited for the Results section.[done](#)

-Given that this work utilizes P6-P8 mice, a disclaimer/ethics statement noting animal work should be added at the beginning of the protocol (e.g., "All procedures involving animal subjects were approved by the Institutional Animal Care and Use Committee...")[done](#)

-Please check that all journal titles are abbreviated in the References section[done](#)

7. The manuscript would benefit from copyediting for grammatical/typographical errors. A subset of these issues are below:

-1.1. Sterilize the dissection materials (one curved scissor, one straight scissor, regular and fine-tip forceps) and the work bench by wiping with 70% ethanol.[done](#)

-1.7. To remove the tibialis anterior... [done](#)

-2.3. Stop digestion by adding 6 mL of Dissection medium and centrifuge the suspension for 5 min at 75 x g to pellet the remaining tissue.[done](#)

-3.2-Wash once with Differentiation medium and switch to new Differentiation medium.[done](#)

8. Additional detail is required

-2.2-To clarify, 50 mL of what? Do you mean a 50 mL conical?done

-3.1-siRNA targeting what? Please provide additional details on the siRNA/DNA mentioned here.done (any of interest)

-3.7-What factors?done

-4.1-What time point?done (any of interest)

-4.7-What concentration of DAPI?done

9. Branding: 2.6-Glutamaxdone

10. Results: Please discuss the individual panels in Figure 1 (especially A and B) and Figure 2 (A, B, and C) in more depth. What are each of these showing? Also, elaborate on the DHPR and TRDN markers in the actual Results text.done

Reviewers' comments:

Reviewer #1:

Manuscript Summary:

This is a good manuscript describing in great detail the optimization of a method that indeed is well known since the early 80'. However this is the first of the dozens of methods available that allows complete maturation of muscle fibres in vitro. As such it is of paramount value to study muscle physiology and, possibly pathology outside of the body.

Although the study is very detailed, two issues should be dealt with while revising the ms:

1. An estimate of cell death during the various steps of dissociation should be provided (a simple Trypan Blue staining would suffice). Cell death assays are not feasible since the tissues are not fully dissociated during the process before the preplating step. The use of trypan blue or other similar methods would be therefore misleading due to cells still be protected in their niches. We do use trypan blue when counting cells for seeding and very rarely see positive cells.

2. We are not told whether these fibres twitch spontaneously or not. In the first case a movie would be informative. Done, in figure 3 we show a calcium spark associated to a spontaneous twitch (it is easier to represent as a figure and adds further information compared to a twitch movie).

Beyond the scope of the present work, it would be interesting to see whether a co-culture with motoneurons would show any specific effect that agrin cannot mimic.

Reference added in results

Also it would be interesting to culture human cells and also DMD cells, also in light of recent claims that iPS-derived DMD muscle cells fail to differentiate.

Major Concerns:

N/A

Minor Concerns:

N/A

Additional Comments to Authors:

N/A

Reviewer #2:

Manuscript Summary:

The manuscript "Isolation of mouse myoblasts for differentiation and imaging of mature myofibers" describes a new protocol for isolation and differentiation of mouse myoblasts.

The protocol is described in full details and list of reagents is complete. The protocol represents a variant of common procedures currently described in the literature to isolate mouse myoblasts. Rat agrin in the medium formulation is used to achieve optimal differentiation.

The protocol is feasible and results are convincing, at least as expression and localization of triadic protein is concerned.

Major Concerns:

N/A

Minor Concerns:

- add a short comment on the main innovation introduced by this protocol compared to traditional approaches should improved the discussion section. done
- please include a comment about the known effect of different batches of serum on the extent of muscle cell differentiation ? Do they affect also this protocol and could chemically-defined medium be used in alternative? Briefly mentioned in step 3.8) and in the discussion. We do test the impact of new batches of Fetal Bovine Serum and Chicken Embryo Extract in cell growth and differentiation. Some products from specific sources or batches have impaired the efficiency of this protocol. We have never tested chemically-defined media.

Additional Comments to Authors:

N/A

Reviewer #3:

Manuscript Summary:

This paper nicely explains a novel approach to grow myotubes in culture that retain structural characteristics that are essential for normal function and which are normally lost in primary myotube cultures. The text is well written, the issues are nearly laid out and I am confident that this will be represent a valuable resource.

Major Concerns:

N/A

Minor Concerns:

N/A

Additional Comments to Authors:

Personally, I'd like to see a higher power image to show the striations in the myotubes clearly in Fig 1. - the striations are visible but only just on my screen. Perhaps an inset would be useful?done

I'd also like to see evidence of function - perhaps this will be shown in a video, but a figure that illustrates shortening or a calcium transient in response to electrical or pharmacological stimulation would add very much to demonstrate the functional differentiation of the preparation.done, figure3